Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

  • ID: 3944264
  • Report
  • Region: Global
  • 161 Pages
  • GBI Research
1 of 5
Gastrointestinal Drugs Market to Hit $48.4 Billion by 2022 As Biologic Products Revolutionize the Treatment Space

FEATURED COMPANIES

  • AbbVie
  • Alexion
  • Allergan
  • AstraZeneca
  • Celgene
  • Johnson & Johnson
  • MORE
Gastrointestinal disorders are common, and a number of them have a large patient population. Across the seven major markets (the US, the UK, France, Germany, Italy, Spain and Japan), gastro esophageal reflux disease (GERD), irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) have patient populations of 148 Million, 41 Million and 2 Million, respectively. For the purpose of this report, IBD comprises Ulcerative Colitis and Crohn’s disease.

The market size for gastrointestinal therapeutics is expected to grow considerably, from USD35.7 Billion in 2015 to USD48.4 Billion in 2022, at a compound annual growth rate (CAGR) of 4.45%. Over a third of the global gastrointestinal market is accounted for by the US, whose market size is expected to increase from USD14.0 Billion in 2015 to USD17.6 Billion in 2022 at a CAGR of 4.51%.

According to Jennifer Goossens, “Recently approved products include Intercept’s Ocaliva, for the treatment of primary biliary cirrhosis, and Takeda’s Takecab for acid-related diseases such as gastroesophageal reflux disease - which are both forecast to generate annual revenue of over USD1 Billion by 2022 - as well as Entyvio for inflammatory bowel disease (IBD).”

There are 937 gastrointestinal pipeline products in active development, most of which are small molecules and biologics. The gastrointestinal therapy area is highly active and has the seventh-largest pipeline across the pharma industry, having more active pipeline products than therapy areas such as respiratory, ophthalmology and dermatology. Over half of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 61%.

The leading companies, Takeda and AbbVie, are expected to maintain their strong positions. In 2015, AbbVie was the leading company in revenue generated from the gastrointestinal market, closely followed by Takeda, with market shares of 19.02% and 18.75%, respectively. By the end of the forecast period, Takeda is expected to overtake AbbVie and become the leading company in gastrointestinal products.

The report “Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape” provides an introduction to the gastrointestinal disease cluster, and some detailed background information regarding the key indications GERD, IBS and IBD. Information is also included regarding symptoms, etiology and pathophysiology, comorbidities and epidemiology.

In particular, this report provides the following:
  • Provides an overview of the gastrointestinal marketed products landscape, including product profiles of key marketed products, and revenue projections for each of these drugs.
  • Analyzes the gastrointestinal pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications GERD, IBS and IBD.
  • Presents forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape for the disease cluster, with an analysis of the key players, the types of company involved, and whether the disease cluster comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyses about trends in co-development and licensing deals relating to gastrointestinal products. Some of the most prominent deals are discussed in detail.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Alexion
  • Allergan
  • AstraZeneca
  • Celgene
  • Johnson & Johnson
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.2.1 Gastroesophageal Reflux Disease
2.2.2 Irritable Bowel Syndrome
2.2.3 Inflammatory Bowel Disease
2.3 Etiology and Pathophysiology
2.3.1 Gastroesophageal Reflux Disease
2.3.2 Irritable Bowel Syndrome
2.3.3 Inflammatory Bowel Disease
2.4 Co-morbidities and Complications
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.5.1 Gastroesophageal Reflux Disease
2.5.2 Irritable Bowel Syndrome
2.5.3 Inflammatory Bowel Disease
2.6 Treatment
2.6.1 Acid-Controlling Agents
2.6.2 Anticholinergics/Antispasmodics
2.6.3 Gastric Stimulants, Laxatives and Antidiarrheals
2.6.4 Anti-inflammatory and Systemic Immunosuppressive Agents
2.6.5 Biologics

3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab)
3.3 Remicade (infliximab)
3.4 Soliris (eculizumab)
3.5 Tysabri (natalizumab)
3.6 Nexium (esomeprazole magnesium)
3.7 Entyvio (vedolizumab)
3.8 Protonix (pantoprazole)
3.9 Ocaliva (obeticholic acid)
3.10 Dexilant (dexlansoprazole)
3.11 Amitiza (lubiprostone)
3.12 Takecab (vonoprazan)
3.13 Linzess (linaclotide)

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Molecule Types in the Pipeline
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Cumulative Clinical Trial Size
4.5 Late-Stage Drugs of the Developmental Pipeline
4.5.1 RPC1063 (ozanimod) - Celgene
4.5.2 GED-0301 (mongersen) - Celgene
4.5.3 Stelara (ustekinumab) - Johnson & Johnson
4.5.4 Victoza (liraglutide) - Novo Nordisk
4.5.5 Plecanatide - Synergy Pharmaceuticals
4.6 Conclusion

5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Tumor Necrosis Factor Alpha
5.3.2 Interleukins and Receptors
5.3.3 H+/K+ ATPase
5.3.4 Integrins

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 AbbVie - Will Patent Expiry of Humira Significantly Diminish Revenues?
6.1.2 Takeda - Will Entyvio and Takecab be the Predominant Contributors to Revenue Growth?
6.1.3 Johnson & Johnson - To What Extent Will Simponi Offset the Patent Expiry of Remicade?
6.1.4 AstraZeneca - Will Patent Expiration of Blockbuster Drug and Lack of Strong Pipeline Line-up Result in Loss of Market Share?
6.1.5 Alexion - Is Soliris’ Success Enough to Drive Strong Company Growth?
6.1.6 Allergan - To What Extent Will Key Gastrointestinal Product Linzess Drive Company Growth?
6.1.7 Celgene - Which Gastrointestinal Pipeline Drugs Will Drive Growth in Second Half of Forecast Period?
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals Valued Above $300m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Molecular Target and Value
7.2.4 Table for Co-development Deals Valued Above $300m

8 Appendix
8.1 References
8.2 Table of Epidemiology Forecast
8.3 Table of All Clinical Stage Pipeline Products
8.4 Abbreviations
8.5 Disease List
8.6 Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Market Size and Revenue Forecasts
8.6.4 Pipeline Analysis
8.6.5 Competitive Landscape
8.7 Contact Us
8.8 Disclaimer

1.1 List of Tables
Table 1: Gastrointestinal Disorders, EU5 and US, Epidemiology of Gastrointestinal Disorders, 2015
Table 2: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Humira, 2016
Table 3: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Remicade, 2016
Table 4: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Soliris, 2016
Table 5: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Tysabri, 2016
Table 6: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Nexium, 2016
Table 7: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Entyvio, 2016
Table 8: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Protonix, 2016
Table 9: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Ocaliva, 2016
Table 10: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Dexilant, 2016
Table 11: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Amitiza, 2016
Table 12: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Takecab, 2016
Table 13: Gastrointestinal Therapeutics Market, Global, Approved Gastrointestinal Indications for Linzess, 2016
Table 14: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
Table 15: Gastrointestinal Therapeutics Market, Global, Usage of Generics Across Key Indications, 2016
Table 16: Gastrointestinal Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022
Table 17: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2016
Table 18: Gastrointestinal Therapeutics Market Therapeutics Market, Global, Co-development Deals, 2006-2016
Table 19: Epidemiology Patterns for Gastroesophageal Reflux Disease, 2015-2022
Table 20: Epidemiology Patterns for Inflammatory Bowel Disease, 2015-2022
Table 21: Epidemiology Patterns for Inflammatory Bowel Disease, 2015-2022
Table 22: Gastrointestinal, Global, Table of all Clinical Stage Pipeline Products, 2016
Table 23: Abbreviations

1.2 List of Figures
Figure 1: Epidemiology Patterns for Gastroesophageal Reflux Disease (million), 2015-2022
Figure 2: Epidemiology Patterns for Irritable Bowel Syndrome (million), 2015-2022
Figure 3: Epidemiology Patterns for Inflammatory Bowel Disease (million), 2015-2022
Figure 4: Gastrointestinal Disorders, Global, Key Marketed Products and Approved Indications, 2016
Figure 5: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2022
Figure 6: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006-2022
Figure 7: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Soliris ($bn), 2006-2022
Figure 8: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Tysabri ($bn), 2010-2022
Figure 9: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Nexium ($bn), 2006-2022
Figure 10: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Entyvio ($bn), 2014-2022
Figure 11: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Protonix ($bn), 2006-2022
Figure 12: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Ocaliva ($bn), 2016-2022
Figure 13: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Dexilant ($bn), 2008-2022
Figure 14: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Amitiza ($bn), 2006-2022
Figure 15: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Takecab ($bn), 2014-2022
Figure 16: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Linzess ($bn), 2012-2022
Figure 17: Gastrointestinal Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 18: Gastrointestinal Therapeutics Market, Global, Gastrointestinal Pipeline by Stage of Development and Molecule Type, 2016
Figure 19: Gastrointestinal Therapeutics Market, Global, Pipeline for Key Gastrointestinal Indications by Stage of Development, 2016
Figure 20: Gastrointestinal Therapeutics Market, Global, Pipeline for Key Gastrointestinal Indications by Molecule Type, 2016
Figure 21: Gastrointestinal Therapeutics Market, Global, Gastrointestinal Pipeline by Molecular Target, 2016
Figure 22: Gastrointestinal Therapeutics Market, Global, Pipeline for Key Gastrointestinal Indications by Molecular Target, 2016
Figure 23: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 24: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 25: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 26: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 27: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 28: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 29: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 30: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 31: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 32: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 33: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 34: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 35: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
Figure 36: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 37: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 38: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 39: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for RPC1063 ($m), 2018-2022
Figure 40: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for GED-0301 ($m), 2018-2022
Figure 41: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for Stelara ($m), 2018-2022
Figure 42: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for Victoza ($m), 2018-2022
Figure 43: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for Plecanatide ($m), 2017-2022
Figure 44: Gastrointestinal Therapeutics Market, Global, Market Size ($bn), 2015-2022
Figure 45: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2015-2022
Figure 46: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Tumor Necrosis Factor Alpha Inhibitors ($bn), 2015-2022
Figure 47: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2018-2022
Figure 48: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for H+/K+ ATPase Inhibitors ($bn), 2015-2022
Figure 49: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Integrin Inhibitors ($bn), 2015-2022
Figure 50: Gastrointestinal Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
Figure 51: Gastrointestinal Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 52: Gastrointestinal Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
Figure 53: Gastrointestinal Therapeutics Market, Global, Revenues by Product Type, 2015-2022
Figure 54: Gastrointestinal Therapeutics Market, Global, AbbVie Annual Revenue Forecast ($bn), 2015-2022
Figure 55: Gastrointestinal Therapeutics Market, Global, Takeda Annual Revenue Forecast ($bn), 2015-2022
Figure 56: Gastrointestinal Therapeutics Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
Figure 57: Gastrointestinal Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2015-2022
Figure 58: Gastrointestinal Therapeutics Market, Global, Alexion Annual Revenue Forecast ($bn), 2015-2022
Figure 59: Gastrointestinal Therapeutics Market, Global, Allergan Annual Revenue Forecast ($bn), 2015-2022
Figure 60: Gastrointestinal Therapeutics Market, Global, Celgene Annual Revenue Forecast ($bn), 2015-2022
Figure 61: Gastrointestinal Therapeutics Market, Global, Companies by Type, 2016
Figure 62: Gastrointestinal Therapeutics Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Gastrointestinal Specialization, 2016
Figure 63: Gastrointestinal Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Gastrointestinal, 2015-2022
Figure 64: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2015
Figure 65: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Indication, 2006-2016
Figure 66: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 67: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2016
Figure 68: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2016
Figure 69: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016
Figure 70: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
Figure 71: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

- AbbVie
- Alexion
- Allergan
- AstraZeneca
- Celgene
- Johnson & Johnson
- Novo Nordisk
- Synergy Pharmaceuticals
- Takeda

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll